NCT03955198View on ClinicalTrials.gov

A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 27, 2021

Primary Completion Date

August 26, 2024

Study Completion Date

August 26, 2024

Conditions
NSCLC
Interventions
COMBINATION_PRODUCT

Radiotherapy + durvalumab

Radiotherapy will be administered in combination with Durvalumab

Trial Locations (8)

Unknown

Institut de Cancérologie de Bourgogne - Auxerre, Auxerre

Institut Sainte-Catherine, Avignon

Centre François Baclesse, Caen

Centre Georges-Francois Leclerc, Dijon

Centre Hospitalier Universitaire Lyon Sud, Lyon

Centre Henri Becquerel, Rouen

CHP Saint Grégoire, Saint-Grégoire

Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse

All Listed Sponsors
lead

Institut Claudius Regaud

OTHER